Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
GE HealthCare Awarded a $44 Million Grant to Develop Artificial Intelligence-Assisted Ultrasound Technology Aimed at Improving Outcomes in Low-and-Middle-Income Countries
Grant from Bill & Melinda Gates Foundation will facilitate development of AI-assisted applications and tools to enable healthcare professionals with less experience to perform quick and accurate ultrasound scans to help address maternal and fetal health and respiratory diseases
AI-assisted ultrasound algorithms will be developed to run on multiple ultrasound devices to expand access to high quality care around the world with an emphasis on low-and-middle income countries (LMIC)
CHICAGO -- GE HealthCare (Nasdaq: GEHC) today announced it received a grant from the Bill & Melinda Gates Foundation for more than $44 million to create user-friendly, artificial intelligence (AI)-assisted ultrasound imaging auto-assessment tools. These tools will seek to aid healthcare professionals—even those without specialized training or experience with ultrasound—with clinical decision information to support more effective obstetric and lung screening ultrasound scans across maternal and fetal care as well as pediatric lung health, with a goal of expanding access to low-and-middle income countries (LMIC) and across diverse sites of care.
From Friday rns
Finally, funding from current NIH grants continues and new funding opportunities are being explored. It is through these grant collaborations with top academic centers that result in the translation of ground-breaking treatments into routine clinical care. We have identified a large new grant opportunity that is specific to our core imaging technologies, and we are evaluating potential aims for a February submission.
Would be great if we could also get a grant from bill gates. Dishing out some of his covid profits lol!!
GLA!!
Shares of Tempest Therapeutics Inc. TPST soared nearly 4,000% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.
The drug candidate, in combination with the Roche Holding AG RHHBY treatments Tecentriq and Avastin, showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer, Tempest said in a release Wednesday.
Further to the announcement made on 18 August 2023, IQAI has cancelled the 396,241 ordinary shares issued to the Mayo Clinic. Following this cancellation, the issued share capital is now 182,225,149 ordinary shares.
I’m signing off for the foreseeable future this game is hard enough to get your head around without games being played by significant holders. They say one thing and do the other. Today’s actions do not give personal investors confidence and are the exact opposite to what we as shareholders were told in an rns.
“The key drivers are all shareholders, who have had to become accustomed to the vagaries of the stock market and how it values the Company`s shares. Oftentimes the market capitalization of the Company has changed over a small number of trading days by 10-25% without any discernable reason”
“We believe that the cumulative accretion of value during this time is not adequately reflected in the current market valuation of the Company, and we are now considering how best to address this anomaly.”
Is this one of those “vagaries” or is it an “anomaly” it would be great if you could update the “ALL SHAREHOLDERS” on why we should buy your company shares while you and your family sell?
Picked up another 580k on the drop, thank you very much!!
Dr. Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology at MCW is the Chair and Co-principal investigator of the study and, along with Co-principal investigator Dr. Jennifer Connelly, MD, Associate Professor of Neurology at MCW, will be enrolling patients in the study. Both are long-standing collaborators with Kathleen Schmainda, PhD, a co-founder of IB and a recognised leader in brain tumour imaging. Together they have researched and developed the use of GaM in preclinical GBM trials. Since the advanced brain tumour imaging offered by IQAI is needed to monitor treatment efficacy for this trial, the investigators approached the Company as a natural partner to provide resources and expertise for this Phase 1 clinical trial.
From the first announcement about the trial
I was told recently. When they have something substantive to say they will and can’t say much more at present in regards to a question about an update on zero G.
This statement from the final results rns makes me think we are due an update soon on this. Probably submission of de novo application .
Using patented artificial intelligence ("AI") technology, IB Zero G generates enhanced "with contrast" images using only non-contrast (0% gadolinium) images as input. The FDA's response to the FDA 510(k) submission concluded that IB Zero G™ was too novel and unique a product and subsequently directed IB to pursue a different regulatory clearance pathway. IB is compiling additional documentation in preparation for a pre-submission meeting with the FDA and plans to submit a "de novo" application in the second half of the year. The de novo request is a market clearance pathway designed for novel medical devices for which no legally marketed predicate device exists to demonstrate substantial equivalence.
This is also from previous updates
In response to how well patients are tolerating the agent and to meet the goal of the phase 1, defining the MTD, the clinical team is preparing an amendment to the original study protocol. The amendment will expand the targeted enrolment from 24 to 36 subjects and allow for continued dose escalation. The MTD determined in Phase 1 will define the "recommended phase II dose" (RP2D) that will be used in the Phase 2 trial. This amendment is the fastest and most efficient way to satisfy the primary goal of the Phase 1.
Given the expanded target enrolment and assuming the strong momentum in patient enrolment continues, it is anticipated that Phase 1 will close in 2024. After enrolment closes, the last patients enrolled will remain on the trial until all required study data is collected. Analysing the data and documenting the phase 1 results is expected to be completed in the second half of 2024.
While the MTD is being determined in the final stages of Phase 1, the clinical team will complete the Phase 2 protocol. The Phase 2 trial is designed to evaluate preliminary evidence of efficacy. Ideally, the Phase II trial will open for patient recruitment in early 2025. This will be a multi-centre trial with a tentative target enrolment of approximately 65 patients over a three-year duration. The design of the Phase 2 study is currently being defined. Factors such as the Phase 1 results and whether the study will be a comparison to historical controls or if it will be randomized (comparing patients with standard treatment alone against those receiving standard treatment with GaM) will influence the overall scope and cost.
The multi-site Phase 2 trial will require new funding which we anticipate will come substantially from a partnership arrangement with a large pharmaceutical company and grants, including those from charitable foundations and other institutions. We anticipate publishing frequent updates to our shareholders as developments unfold.
It just says
Experimental: Dose-expansion Phase
A minimum of six participants will be enrolled in the dose expansion phase for a total of 12 subjects at the recommended phase 2 dose.
Drug: Gallium maltolate (recommended phase 2 dose)
The maximum-tolerated dose (recommended phase 2 dose).
Other Names:
CAS 108560-70-9
Hopefully means we will receive an update soon.
GLA!!
Again in another study, IB’s proprietary standardized rCBV (perfusion) technology in IB Neuro shows the best reproducibility/consistency compared to normalized rCBV available from other vendors. And, normalizing rCBV values requires manual input ... IB Neuro is fully automated
Twitter account in overdrive mode tonight!!
@IQAI_IB
's IB Neuro offers multiple exclusive features for MR perfusion, but it also automatically processes CT perfusion maps (including auto AIF detection). Front end intelligence determines the type of data to be processed (MR or CT) and executes the appropriate algorithm.
Nice pickup of the recently published study...
Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR
“The study demonstrates that a single dose (no preload), low flip angle method does not compromise image quality,” said Dr. Mark Shiroishi, MD. “This is a great added benefit for patients who may have concerns about GBCA risks, and for administrators looking for opportunities to curtail operational expenses”.
https://www.itnonline.com/content/reduced-gadolinium-approach-validated-ib-neuro-15t-mr-scanners
Shared by a client - another case showing how IB Delta T1 maps (patent-pending) and IB Neuro (quantitative rCBV) can impact treatment decisions.
Pre-surgical MRI shows a concerning lesion on T1+C.
Post-surgical pathological diagnosis = No tumor
IB Software = No tumor
https://twitter.com/IQAI_IB/status/1704965865752481974
Amrami says the most important objective of this research is to demonstrate, and raise awareness around, the clinical need for these solutions.
“The determination of what constitutes quality care and how to generalize that is an important question that has to be addressed through investigation and reliable data in terms of the impact of medical imaging and theranostics on improving patient outcomes,” she said.
GE HealthCare has embarked on a number of collaborations in both these areas. In August, it teamed up with Imaging Biometrics, a subsidiary of IQ-AI, agreeing to use its MR Smart Subscription solution to distribute IB Neuro and IB Delta T1 applications to more MR providers. These applications use MR brain imaging data to create quantitative, proprietary mapped images that streamline scan acquisitions, processing, and readings.
https://www.dotmed.com/news/story/61239
Nice to see us mentioned in this article
And yes added another 650k to the pile today can’t believe you can still buy pound coins for pennies!
GLA!!
Blackfords was acquired shortly after their collaboration with bayer IQAI have entered a collaboration with bayer and recently GE could we be about to see a cheeky bid to buy us out? If Trevor didn’t sell any of his holding at 20p and with all the positive news regarding the trial I wonder what could entice him
GLA!